共 50 条
The Skin Microbiome of Patients With Atopic Dermatitis Normalizes Gradually During Treatment
被引:43
|作者:
Khadka, Veda D.
[1
,2
]
Key, Felix M.
[1
,2
,5
]
Romo-Gonzalez, Carolina
[3
]
Martinez-Gayosso, Adrian
[4
]
Campos-Cabrera, Blanca L.
[4
]
Geronimo-Gallegos, Armando
[3
]
Lynn, Tucker C.
[1
,2
]
Duran-McKinster, Carola
[4
]
Coria-Jimenez, Rafael
[3
]
Lieberman, Tami D.
[1
,2
]
Garcia-Romero, Maria T.
[4
]
机构:
[1] MIT, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA
[2] MIT, Dept Civil & Environm Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA
[3] Natl Inst Pediat, Expt Bacteriol Lab, Mexico City, DF, Mexico
[4] Natl Inst Pediat, Dept Dermatol, Mexico City, DF, Mexico
[5] Max Planck Inst Infect Biol, Berlin, Germany
来源:
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
|
2021年
/
11卷
关键词:
atopic dermatitis (AD);
microbiome & dysbiosis;
skin;
microbiota (16S);
therapeutics;
STAPHYLOCOCCUS-AUREUS;
BLEACH BATHS;
DISEASE;
COLONIZATION;
D O I:
10.3389/fcimb.2021.720674
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
Background Atopic dermatitis (AD) is characterized by an altered skin microbiome dominantly colonized by S. aureus. Standard treatment includes emollients, anti-inflammatory medications and antiseptics.</p> Objectives To characterize changes in the skin microbiome during treatment for AD.</p> Methods The skin microbiomes of children with moderate-to-severe AD and healthy children were investigated in a longitudinal prospective study. Patients with AD were randomized to receive either standard treatment with emollients and topical corticosteroids or standard treatment with the addition of dilute bleach baths (DBB) and sampled at four visits over a three-month period. At each visit, severity of AD was measured, swabs were taken from four body sites and the composition of the microbiome at those sites was assessed using 16S rRNA amplification.</p> Results We included 14 healthy controls and 28 patients. We found high relative abundances of S. aureus in patients, which correlated with AD severity and reduced apparent alpha diversity. As disease severity improved with treatment, the abundance of S. aureus decreased, gradually becoming more similar to the microbiomes of healthy controls. After treatment, patients who received DBB had a significantly lower abundance of S. aureus than those who received only standard treatment.</p> Conclusions There are clear differences in the skin microbiome of healthy controls and AD patients that diminish with treatment. After three months, the addition of DBB to standard treatment had significantly decreased the S. aureus burden, supporting its use as a therapeutic option. Further study in double-blinded trials is needed.</p>
引用
收藏
页数:10
相关论文